Vida’s new offering integrates obesity treatment, lifestyle intervention, and longitudinal coaching to support people living with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).
SAN FRANCISCO–(BUSINESS WIRE)–Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity, diabetes, and related conditions, today announced the expansion of its clinical portfolio to include support for patients living with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). Vida’s new MASH treatment combines lifestyle changes, medication management, behavioral health, and longitudinal coaching. The offering further expands the company’s comprehensive obesity care solutions for employers and health plans navigating the rising costs of treating complex, obesity-related conditions.
MASH, a progressive liver disease that affects an estimated 5% of U.S. adults, is closely linked to obesity, type 2 diabetes, dyslipidemia, and hypertension. With the recent FDA approval of GLP-1 medications for noncirrhotic MASH with moderate to advanced liver fibrosis, the industry faces new challenges in identifying appropriate patients, managing long-term treatment, and controlling costs. Vida’s personalized model is designed to help fill that gap with structured, evidence-based care.
“Obesity is a common thread connecting many of the most costly and complex chronic conditions employers and health plans face today,” said Joe Murad, CEO at Vida Health. “By expanding our obesity care model to include support for people living with MASH, Vida is providing a whole-person approach to help members improve their health, while helping our partners manage GLP-1 spend and patient treatments.”
Vida’s MASH treatment model complements the care provided by hepatologists, endocrinologists, obesity medicine, and other MASH specialists by delivering comprehensive lifestyle interventions, behavioral health support, and GLP-1 prescribing only when medically necessary. Vida assesses each patient’s risk factors, health history and status, and previous obesity treatments to develop personalized, clinically validated care plans for each patient. Vida’s convenient telehealth platform provides continuous monitoring, coaching, and medical oversight from a team of clinicians, leading to significant and sustained weight loss outcomes to help slow or prevent MASH progression.
For employers and health plans, Vida brings a proven track record of clinical outcomes and GLP-1 spend trend mitigation to its new MASH offering. By prescribing responsively and prioritizing comprehensive lifestyle interventions and lower-cost therapies when appropriate, Vida delivers a cost-effective, evidence-based treatment path alternative to the growing number of new FDA-approved GLP-1 indications.
To learn more about Vida’s new MASH program, visit www.vida.com/mash.
About Vida Health
Vida Health is a virtual, personalized obesity care provider that helps patients manage obesity and related conditions like diabetes, high blood pressure, anxiety, and depression with evidence-based treatment. Vida’s team of obesity medicine-certified physicians, nurses, registered dietitians, expert coaches, and licensed therapists takes a whole-person approach, leading to clinically meaningful body weight loss in one year. Practicing responsible prescribing, Vida supports patients, employers, and health plans by prioritizing proven behavior change and lifestyle interventions before introducing medications, ensuring that only those who really need anti-obesity medications receive them — helping to control costs. For individuals with obesity, employers and health plans can save up to $550 in monthly prescription costs. Vida serves members in all 50 states and Washington, D.C., offers services in both English and Spanish, and operates on a value-based pricing model, putting outcomes at the center of care. To learn more, visit www.vida.com.
Contacts
PR Contact
Sage D’Amico
BIG FISH PR for Vida Health
[email protected]
